NEW YORK (GenomeWeb) – Clontech Laboratories today announced a non-exclusive licensing deal with the Broad Institute for its CRISPR-Cas9 technology.

The deal provides Clontech, a wholly owned subsidiary of Takara Bio, access to the intellectual property surrounding the technology. The US Patent and Trademark Office granted the Broad the first patent for the CRISPR-Cas9 technology earlier this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.